These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26308228)

  • 1. Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population.
    Modi A; Gold DT; Yang X; Fan CP; Sajjan SG
    J Manag Care Spec Pharm; 2015 Sep; 21(9):811-21. PubMed ID: 26308228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population.
    Modi A; Siris S; Yang X; Fan CP; Sajjan S
    J Manag Care Spec Pharm; 2015 Jun; 21(6):499-506. PubMed ID: 26011551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis.
    Cortet B; Modi A; Tang J; Fan CP; Sajjan S; Weaver JP
    BMC Musculoskelet Disord; 2016 Apr; 17():195. PubMed ID: 27139225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.
    Yu J; Goldshtein I; Shalev V; Chodick G; Ish-Shalom S; Sharon O; Modi A
    Int J Clin Pract; 2015 Sep; 69(9):1007-14. PubMed ID: 26278464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.
    Siris ES; Yu J; Bognar K; DeKoven M; Shrestha A; Romley JA; Modi A
    Clin Interv Aging; 2015; 10():1813-24. PubMed ID: 26604724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
    Modi A; Siris ES; Steve Fan CP; Sajjan S
    Clin Ther; 2015 Jun; 37(6):1228-34. PubMed ID: 25866298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and consequences of noncompliance to oral bisphosphonate treatment.
    Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
    J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver J; van den Bergh JP; Nguyen AM; Sajjan S;
    Osteoporos Int; 2016 Mar; 27(3):1227-1238. PubMed ID: 26637321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population.
    Modi A; Sajjan S; Michael Lewiecki E; Harris ST; Papadopoulos Weaver J
    Clin Ther; 2016 May; 38(5):1074-80. PubMed ID: 27112533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.
    Modi A; Ebeling PR; Lee MS; Min YK; Mithal A; Yang X; Baidya S; Sen S; Sajjan S
    Arch Osteoporos; 2017 Dec; 12(1):65. PubMed ID: 28718004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
    Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
    Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study.
    Woo C; Gao G; Wade S; Hochberg MC
    Curr Med Res Opin; 2010 Apr; 26(4):1003-9. PubMed ID: 20201623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.
    Dömötör ZR; Vörhendi N; Hanák L; Hegyi P; Kiss S; Csiki E; Szakó L; Párniczky A; Erőss B
    Front Endocrinol (Lausanne); 2020; 11():573976. PubMed ID: 33240217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative gastrointestinal safety of weekly oral bisphosphonates.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Levin R; Solomon DH
    Osteoporos Int; 2009 Oct; 20(10):1735-47. PubMed ID: 19266138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
    Tadrous M; Wong L; Mamdani MM; Juurlink DN; Krahn MD; Lévesque LE; Cadarette SM
    Osteoporos Int; 2014 Apr; 25(4):1225-35. PubMed ID: 24287510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
    Siris ES; Modi A; Tang J; Gandhi S; Sen S
    Curr Med Res Opin; 2014 Jan; 30(1):123-30. PubMed ID: 24102262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.